Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Integrative genomic, single-cell, and functional profiling uncovers immune consequences of the CD48–CD244 axis in NK cells in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

BPBonell Patiño-EscobarLPLucy Perez-LugoSRSham Rampersaud

Discussion

Loading...

Member takes

Overview

Integrative genomic analysis reveals CD48–CD244 signaling as a key regulator of NK cell function and exhaustion in multiple myeloma.

Key Points

  • The study aims to understand how the CD48–CD244 axis affects NK cell function in multiple myeloma.
  • Conducted bulk and single-cell RNA-seq, ATAC-seq, and CRISPR screens.
  • Analyzed gene expression and regulatory networks relating to NK cell functionality.
  • Used murine modeling to observe NK cell behavior in the context of multiple myeloma.
  • CD48 expression levels correlate with poor survival in patients with high-risk multiple myeloma.
  • Enhanced NK activation occurs with CD48 overexpression, while CD48 knockout impairs NK cell function.
  • Analysis of NK cells in multiple myeloma reveals markers of exhaustion and dysfunctional signaling.

Cite This Study

Patiño-Escobar et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de42https://doi.org/10.1182/blood-2025-687
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1NK cells with adhesion defects and reduced cytotoxic functions are associated with a poor prognosis in multiple myeloma2024 · 21 citations
  2. 2NK cell dysregulation in the multiple myeloma: insights from multi-modal profiling of the bone marrow microenvironment 28122025
  3. 3High-dimensional profiling reveals predominant depletion of NK cell effector phenotypes in relapsed/refractory multiple myeloma patients treated with anti-CD38 therapy2025
  4. 4Therapeutic targeting of CD47 using a tri-specific NK cell engager to inhibit multiple myeloma2026
  5. 5Coevolution of NK and Tumor Cell States Along Multiple Myeloma Progression from Precursor Conditions2026